|
1
|
Behera SK, Praharaj AB, Dehury B and Negi
S: Exploring the role and diversity of mucins in health and disease
with special insight into non-communicable diseases. Glyconconj J.
32:575–613. 2015. View Article : Google Scholar
|
|
2
|
Dhanisha SS, Guruvayoorappan C, Drishya S
and Abeesh P: Mucins: Structural diversity, biosynthesis, its role
in pathogenesis and as possible therapeutic targets. Crit Rev Oncol
Hematol. 122:98–122. 2018. View Article : Google Scholar
|
|
3
|
Cornick S, Tawiah A and Chadee K: Roles
and regulation of the mucus barrier in the gut. Tissue Barriers.
3:e9824262015. View Article : Google Scholar
|
|
4
|
Moniaux N, Escande F, Porchet N, Aubert JP
and Batra SK: Structural organization and classification of the
human mucin genes. Front Biosci. 6:D1192–D1206. 2001. View Article : Google Scholar
|
|
5
|
Nath S and Mukherjee P: MUC1: A
multifaceted oncoprotein with a key role in cancer progression.
Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar
|
|
6
|
Hanson RL and Hollingsworth MA: Functional
consequences of differential O-glycosylation of MUC1, MUC4, and
MUC16 (downstream effects on signaling). Biomolecules. 6:342016.
View Article : Google Scholar
|
|
7
|
Jonckheere N and Van Seuningen I: The
membrane-bound mucins: How large O-glycoproteins play key roles in
epithelial cancers and hold promise as biological tools for
gene-based and immunotherapies. Crit Rev Oncog. 14:177–196. 2008.
View Article : Google Scholar
|
|
8
|
Lau SK, Weiss LM and Chu PG: Differential
expression of MUC1, MUC2, and MUC5AC in carcinomas of various
sites: An immunohistochemical study. Am J Clin Pathol. 122:61–69.
2004. View Article : Google Scholar
|
|
9
|
Reynolds IS, Fichtner M, McNamara DA, Kay
EW, Prehn JHM and Burke JP: Mucin glycoproteins block apoptosis;
promote invasion, proliferation, and migration; and cause
chemoresistance through diverse pathways in epithelial cancers.
Cancer Metastasis Rev. 38:237–257. 2019. View Article : Google Scholar
|
|
10
|
Altschuler Y, Kinlough CL, Poland PA,
Bruns JB, Apodaca G, Weisz OA and Hughey RP: Clathrin-mediated
endocytosis of MUC1 is modulated by its glycosylation state. Mol
Biol Cell. 11:819–831. 2000. View Article : Google Scholar
|
|
11
|
Katoch B, Sebastian S, Sahdev S, Padh H,
Hasnain SE and Begum R: Programmed cell death and its clinical
implications. Indian J Exp Biol. 40:513–524. 2002.
|
|
12
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar
|
|
13
|
D'Arcy MS: Cell death: A review of the
major forms of apoptosis, necrosis and autophagy. Cell Biol Int.
43:582–592. 2019. View Article : Google Scholar
|
|
14
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar
|
|
15
|
Jan R and Chaudhry GE: Understanding
apoptosis and apoptotic pathways targeted cancer therapeutics. Adv
Pharm Bull. 9:205–218. 2019. View Article : Google Scholar
|
|
16
|
Papaliagkas V, Anogianaki A, Anogianakis G
and Ilonidis G: The proteins and the mechanisms of apoptosis: A
mini-review of the fundamentals. Hippokratia. 11:108–113. 2007.
|
|
17
|
Taylor R, Cullen S and Martin S:
Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol
Cell Biol. 9:231–241. 2008. View Article : Google Scholar
|
|
18
|
Shakeri R, Kheirollahi A and Davoodi J:
Apaf-1: Regulation and function in cell death. Biochimie.
135:111–125. 2017. View Article : Google Scholar
|
|
19
|
Shimizu S, Narita M and Tsujimoto Y: Bcl-2
family proteins regulate the release of apoptogenic cytochrome c by
the mitochondrial channel VDAC. Nature. 399:483–487. 1999.
View Article : Google Scholar
|
|
20
|
Savitskaya MA and Onishchenko GE:
Mechanisms of apoptosis. Biochemistry (Mosc). 80:1393–1405. 2015.
View Article : Google Scholar
|
|
21
|
O'Brien MA and Kirby R: Apoptosis: A
review of pro-apoptotic and anti-apoptotic pathways and
dysregulation in disease. J Vet Emerg Crit Care (San Antonio).
18:572–585. 2008. View Article : Google Scholar
|
|
22
|
Julien O and Wells JA: Caspases and their
substrates. Cell Death Differ. 24:1380–1389. 2017. View Article : Google Scholar
|
|
23
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar
|
|
24
|
Van Ba H and Hwang I: Role of caspase-9 in
the effector caspases and genome expressions, and growth of bovine
skeletal myoblasts. Dev Growth Differ. 56:131–142. 2014. View Article : Google Scholar
|
|
25
|
Dempsey PW, Doyle SE, He JQ and Cheng G:
The signaling adaptors and pathways activated by TNF superfamily.
Cytokine Growth Factor Rev. 14:193–209. 2003. View Article : Google Scholar
|
|
26
|
Srivastava RK: TRAIL/Apo-2L: Mechanisms
and clinical applications in cancer. Neoplasia. 3:535–546. 2001.
View Article : Google Scholar
|
|
27
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar
|
|
28
|
Luo X, Budihardjo I, Zou H, Slaughter C
and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c
release from mitochondria in response to activation of cell surface
death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar
|
|
29
|
Valentijn AJ and Gilmore AP: Translocation
of full-length Bid to mitochondria during anoikis. J Biol Chem.
279:32848–32857. 2004. View Article : Google Scholar
|
|
30
|
Woods NT, Yamaguchi H, Lee FY, Bhalla KN
and Wang HG: Anoikis, initiated by Mcl-1 degradation and Bim
induction, is deregulated during oncogenesis. Cancer Res.
67:10744–10752. 2007. View Article : Google Scholar
|
|
31
|
Zhao Q, Piyush T, Chen C, Hollingsworth
MA, Hilkens J, Rhodes JM and Yu LG: MUC1 extracellular domain
confers resistance of epithelial cancer cells to anoikis. Cell
Death Dis. 5:e14382014. View Article : Google Scholar
|
|
32
|
Kim YN, Koo KH, Sung JY, Yun UJ and Kim H:
Anoikis resistance: An essential prerequisite for tumor metastasis.
Int J Cell Biol. 2012:3068792012. View Article : Google Scholar
|
|
33
|
Paoli P, Giannoni E and Chiarugi P:
Anoikis molecular pathways and its role in cancer progression.
Biochim Biophys Acta. 1833:3481–3498. 2013. View Article : Google Scholar
|
|
34
|
Yang MC, Lin RW, Huang SB, Huang SY, Chen
WJ, Wang S, Hong YR and Wang C: Bim directly antagonizes Bcl-xl in
doxorubicin-induced prostate cancer cell apoptosis independently of
p53. Cell Cycle. 15:394–402. 2016. View Article : Google Scholar
|
|
35
|
Aoudjit F and Vuori K: Matrix attachment
regulates Fas-induced apoptosis in endothelial cells: A role for
c-flip and implications for anoikis. J Cell Biol. 152:633–643.
2001. View Article : Google Scholar
|
|
36
|
Marconi A, Atzei P, Panza C, Fila C,
Tiberio R, Truzzi F, Wachter T, Leverkus M and Pincelli C:
FLICE/caspase-8 activation triggers anoikis induced by
beta1-integrin blockade in human keratinocytes. J Cell Sci.
117:5815–5823. 2004. View Article : Google Scholar
|
|
37
|
Hattrup CL and Gendler SJ: Structure and
function of the cell surface (tethered) mucins. Annu Rev Physiol.
70:431–457. 2008. View Article : Google Scholar
|
|
38
|
Singh PK and Hollingsworth MA: Cell
surface-associated mucins in signal transduction. Trends Cell Biol.
16:467–476. 2006. View Article : Google Scholar
|
|
39
|
Hagiwara M, Yasumizu Y, Yamashita N,
Rajabi H, Fushimi A, Long MD, Li W, Bhattacharya A, Ahmad R, Oya M,
et al: MUC1-C Activates the BAF (mSWI/SNF) complex in prostate
cancer stem cells. Cancer Res. 81:1111–1122. 2021. View Article : Google Scholar
|
|
40
|
Hanson JM, BroweIl DA, Cunliffe WJ, Varma
J, Allen A, Hemming D, Shenton BK, Young JR, Higgs MJ, Brotherick I
and Pearson JP: MUC1 expression in primary breast cancer: The
effect of tamoxifen treatment. Breast Cancer Res Treat. 67:215–222.
2001. View Article : Google Scholar
|
|
41
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar
|
|
42
|
Raina D, Ahmad R, Rajabi H, Panchamoorthy
G, Kharbanda S and Kufe D: Targeting cysteine-mediated dimerization
of the MUC1-C oncoprotein in human cancer cells. Int J Oncol.
40:1643–1649. 2012.
|
|
43
|
Yang J: Identification of novel
biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer. Med
Oncol. 37:342020. View Article : Google Scholar
|
|
44
|
Apostolopoulos V, Stojanovska L and
Gargosky SE: MUC1 (CD227): A multi-tasked molecule. Cell Mol Life
Sci. 72:4475–4500. 2015. View Article : Google Scholar
|
|
45
|
Taylor-Papadimitriou J: Report on the
first international workshop on carcinoma-associated mucins. Int J
Cancer. 49:1–5. 1991. View Article : Google Scholar
|
|
46
|
Gendler SJ and Spicer AP: Epithelial mucin
genes. Annu Rev Physiol. 57:607–634. 1995. View Article : Google Scholar
|
|
47
|
Hanisch FG and Müller S: MUC1: The
polymorphic appearance of a human mucin. Glycobiology. 10:439–449.
2000. View Article : Google Scholar
|
|
48
|
Agrawal B, Krantz MJ, Parker J and
Longenecker BM: Expression of MUC1 mucin on activated human T
cells: Implications for a role of MUC1 in normal immune regulation.
Cancer Res. 58:4079–4081. 1998.
|
|
49
|
Dent GA, Civalier CJ, Brecher ME and
Bentley SA: MUC1 expression in hematopoietic tissues. Am J Clin
Pathol. 111:741–747. 1999. View Article : Google Scholar
|
|
50
|
Franke FE, Kraus S, Eiermann C, Pauls K,
Lalani EN and Bergmann M: MUC1 in normal and impaired
spermatogenesis. Mol Hum Reprod. 7:505–512. 2001. View Article : Google Scholar
|
|
51
|
Seo JT, Lee JS, Jun JH and Yang MH:
Expression of mucin genes in the human testis and its relationship
to spermatogenesis. Yonsei Med J. 46:667–672. 2005. View Article : Google Scholar
|
|
52
|
Cascio S and Finn OJ: Intra- and
extra-cellular events related to altered glycosylation of MUC1
promote chronic inflammation, tumor progression, invasion, and
metastasis. Biomolecules. 6:392016. View Article : Google Scholar
|
|
53
|
Bennett EP, Mandel U, Clausen H, Gerken
TA, Fritz TA and Tabak LA: Control of mucin-type O-glycosylation: A
classification of the polypeptide GalNAc-transferase gene family.
Glycobiology. 22:736–756. 2012. View Article : Google Scholar
|
|
54
|
Taherali F, Varum F and Basit AW: A
slippery slope: On the origin, role and physiology of mucus. Adv
Drug Deliv Rev. 124:16–33. 2018. View Article : Google Scholar
|
|
55
|
Raina D, Agarwal P, Lee J, Bharti A,
McKnight CJ, Sharma P, Kharbanda S and Kufe D: Characterization of
the MUC1-C cytoplasmic domain as a cancer target. PLoS One.
10:e01351562015. View Article : Google Scholar
|
|
56
|
McAuley JL, Corcilius L, Tan HX, Payne RJ,
McGuckin MA and Brown LE: The cell surface mucin MUC1 limits the
severity of influenza A virus infection. Mucosal Immunol.
10:1581–1593. 2017. View Article : Google Scholar
|
|
57
|
Thathiah A, Blobel CP and Carson DD: Tumor
necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1
shedding. J Biol Chem. 278:3386–3394. 2003. View Article : Google Scholar
|
|
58
|
Tarp MA and Clausen H: Mucin-type
O-glycosylation and its potential use in drug and vaccine
development. Biochim Biophys Acta. 1780:546–563. 2008. View Article : Google Scholar
|
|
59
|
Awaya H, Takeshima Y, Yamasaki M and Inai
K: Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical
adenomatous hyperplasia, bronchioloalveolar carcinoma,
adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar
carcinoma of the lung. Am J Clin Pathol. 121:644–653. 2004.
View Article : Google Scholar
|
|
60
|
Horm TM and Schroeder JA: MUC1 and
metastatic cancer: Expression, function and therapeutic targeting.
Cell Adh Migr. 7:187–198. 2013. View Article : Google Scholar
|
|
61
|
Krishn SR, Kaur S, Smith LM, Johansson SL,
Jain M, Patel A, Gautam SK, Hollingsworth MA, Mandel U, Clausen H,
et al: Mucins and associated glycan signatures in colon
adenoma-carcinoma sequence: Prospective pathological implication(s)
for early diagnosis of colon cancer. Cancer Lett. 374:304–314.
2016. View Article : Google Scholar
|
|
62
|
Singh AP, Chauhan SC, Bafna S, Johansson
SL, Smith LM, Moniaux N, Lin MF and Batra SK: Aberrant expression
of transmembrane mucins, MUC1 and MUC4, in human prostate
carcinomas. Prostate. 66:421–429. 2006. View Article : Google Scholar
|
|
63
|
Gao Y, Liu Z, Feng J, Sun Q, Zhang B,
Zheng W and Ma W: Expression pattern of polypeptide
N-acetylgalactosaminyltransferase-10 in gastric carcinoma. Oncol
Lett. 5:113–116. 2013. View Article : Google Scholar
|
|
64
|
Guda K, Moinova H, He J, Jamison O, Ravi
L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, et al:
Inactivating germ-line and somatic mutations in polypeptide
N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc
Natl Acad Sci USA. 106:12921–12925. 2009. View Article : Google Scholar
|
|
65
|
Stowell SR, Ju T and Cummings RD: Protein
glycosylation in cancer. Annu Rev Pathol. 10:473–510. 2015.
View Article : Google Scholar
|
|
66
|
Liesche F, Kölbl AC, Ilmer M, Hutter S,
Jeschke U and Andergassen U: Role of
N-acetylgalactosaminyltransferase 6 in early tumorigenesis and
formation of metastasis. Mol Med Rep. 13:4309–4314. 2016.
View Article : Google Scholar
|
|
67
|
Hakomori S: Aberrant glycosylation in
cancer cell membranes as focused on glycolipids: Overview and
perspectives. Cancer Res. 45:2405–2414. 1985.
|
|
68
|
Radziejewska I, Supruniuk K, Nazaruk J,
Karna E, Popławska B, Bielawska A and Galicka A: Rosmarinic acid
influences collagen, MMPs, TIMPs, glycosylation and MUC1 in
CRL-1739 gastric cancer cell line. Biomed Pharmacother.
107:397–407. 2018. View Article : Google Scholar
|
|
69
|
Syrkina MS, Maslakova AA, Potashnikova DM,
Veiko VP, Vassetzky YS and Rubtsov MA: Dual role of the
extracellular domain of human mucin MUC1 in metastasis. J Cell
Biochem. 118:4002–4011. 2017. View Article : Google Scholar
|
|
70
|
Ho WL, Hsu WM, Huang MC, Kadomatsu K and
Nakagawara A: Protein glycosylation in cancers and its potential
therapeutic applications in neuroblastoma. J Hematol Oncol.
9:1002016. View Article : Google Scholar
|
|
71
|
Liu B, Pan S, Xiao Y, Liu Q, Xu J and Jia
L: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer
progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway.
J Exp Clin Cancer Res. 37:3162018. View Article : Google Scholar
|
|
72
|
Mao Y, Zhang Y, Fan S, Chen L, Tang L,
Chen X and Lyu J: GALNT6 promotes tumorigenicity and metastasis of
breast cancer cell via β-catenin/MUC1-C signaling pathway. Int J
Biol Sci. 15:169–182. 2019. View Article : Google Scholar
|
|
73
|
Bäckström M, Thomsson KA, Karlsson H and
Hansson GC: Sensitive liquid chromatography-electrospray mass
spectrometry allows for the analysis of the O-glycosylation of
immunoprecipitated proteins from cells or tissues: Application to
MUC1 glycosylation in cancer. J Proteome Res. 8:538–545. 2009.
View Article : Google Scholar
|
|
74
|
Blanas A, Sahasrabudhe NM, Rodríguez E,
van Kooyk Y and van Vliet SJ: Fucosylated antigens in cancer: An
alliance toward tumor progression, metastasis, and resistance to
chemotherapy. Front Oncol. 8:392018. View Article : Google Scholar
|
|
75
|
Jia L, Zhang J, Ma T, Guo Y, Yu Y and Cui
J: The Function of Fucosylation in Progression of Lung Cancer.
Front Oncol. 8:5652018. View Article : Google Scholar
|
|
76
|
Chen Z, Gulzar ZG, St Hill CA, Walcheck B
and Brooks JD: Increased expression of GCNT1 is associated with
altered O-glycosylation of PSA, PAP, and MUC1 in human prostate
cancers. Prostate. 74:1059–1067. 2014. View Article : Google Scholar
|
|
77
|
Nakamori S, Kameyama M, Imaoka S, Furukawa
H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y and
Irimura T: Increased expression of sialyl Lewisx antigen correlates
with poor survival in patients with colorectal carcinoma:
Clinicopathological and immunohistochemical study. Cancer Res.
53:3632–3637. 1993.
|
|
78
|
Ricardo S, Marcos-Silva L, Valente C,
Coelho R, Gomes R and David L: Mucins MUC16 and MUC1 are major
carriers of SLe(a) and SLe(x) in borderline and malignant serous
ovarian tumors. Virchows Arch. 468:715–722. 2016. View Article : Google Scholar
|
|
79
|
Mori Y, Akita K, Yashiro M, Sawada T,
Hirakawa K, Murata T and Nakada H: Binding of galectin-3, a
β-galactoside-binding lectin, to MUC1 protein enhances
phosphorylation of extracellular signal-regulated kinase 1/2
(ERK1/2) and Akt, promoting tumor cell malignancy. J Biol Chem.
290:26125–26140. 2015. View Article : Google Scholar
|
|
80
|
Ramasamy S, Duraisamy S, Barbashov S,
Kawano T, Kharbanda S and Kufe D: The MUC1 and galectin-3
oncoproteins function in a microRNA-dependent regulatory loop. Mol
Cell. 27:992–1004. 2007. View Article : Google Scholar
|
|
81
|
Sciacchitano S, Lavra L, Morgante A,
Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB and
Ricci A: Galectin-3: One molecule for an alphabet of diseases, from
A to Z. Int J Mol Sci. 19:3792018. View Article : Google Scholar
|
|
82
|
Zhao Q, Guo X, Nash GB, Stone PC, Hilkens
J, Rhodes JM and Yu LG: Circulating galectin-3 promotes metastasis
by modifying MUC1 localization on cancer cell surface. Cancer Res.
69:6799–6806. 2009. View Article : Google Scholar
|
|
83
|
Kufe DW: MUC1-C oncoprotein as a target in
breast cancer: Activation of signaling pathways and therapeutic
approaches. Oncogene. 32:1073–1081. 2013. View Article : Google Scholar
|
|
84
|
Ren J, Agata N, Chen D, Li Y, Yu WH, Huang
L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1
carcinoma-associated protein confers resistance to genotoxic
anticancer agents. Cancer Cell. 5:163–175. 2004. View Article : Google Scholar
|
|
85
|
Yin L and Kufe D: Human MUC1 carcinoma
antigen regulates intracellular oxidant levels and the apoptotic
response to oxidative stress. J Biol Chem. 278:35458–35464. 2003.
View Article : Google Scholar
|
|
86
|
Baldwin AS: Control of oncogenesis and
cancer therapy resistance by the transcription factor NF-κB. J Clin
Invest. 107:241–246. 2001. View Article : Google Scholar
|
|
87
|
Dyomin VG, Palanisamy N, Lloyd KO, Dyomina
K, Jhanwar SC, Houldsworth J and Chaganti RS: MUC1 is activated in
a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is
rearranged and amplified in B-cell lymphoma subsets. Blood.
95:2666–2671. 2000. View Article : Google Scholar
|
|
88
|
Nakshatri H, Bhat-Nakshatri P, Martin DA,
Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-κB
during progression of breast cancer to hormone-independent growth.
Mol Cell Biol. 17:3629–3639. 1997. View Article : Google Scholar
|
|
89
|
Stroopinsky D, Rosenblatt J, Ito K, Mills
H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, et al:
MUC1 is a potential target for the treatment of acute myeloid
leukemia stem cells. Cancer Res. 73:5569–5579. 2013. View Article : Google Scholar
|
|
90
|
Li Y, Yu WH, Ren J, Huang L, Kharbanda S,
Loda M and Kufe D: Heregulin targets γ-catenin to the nucleolus by
a mechanism dependent on the DF3/MUC1 protein. Mol Cancer Res.
1:765–775. 2003.
|
|
91
|
Agata N, Ahmad R, Kawano T, Raina D,
Kharbanda S and Kufe D: MUC1 oncoprotein blocks death
receptor-mediated apoptosis by inhibiting recruitment of caspase-8.
Cancer Res. 68:6136–6144. 2008. View Article : Google Scholar
|
|
92
|
Ahmad R, Raina D, Trivedi V, Ren J, Rajabi
H, Kharbanda S and Kufe D: MUC1 oncoprotein activates the IkappaB
kinase beta complex and constitutive NF-kappaBsignalling. Nat Cell
Biol. 9:1419–1427. 2007. View Article : Google Scholar
|
|
93
|
Escher TE, Lui AJ, Geanes ES, Walter KR,
Tawfik O, Hagan CR and Lewis-Wambi J: Interaction between MUC1 and
STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant
breast cancer cells and mediates estrogen-induced apoptosis. Mol
Cancer Res. 17:1180–1194. 2019. View Article : Google Scholar
|
|
94
|
Pistritto G, Trisciuoglio D, Ceci C,
Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: Function
and dysfunction of its modulators and targeted therapeutic
strategies. Aging (Albany NY). 8:603–619. 2016. View Article : Google Scholar
|
|
95
|
Comalada M, Xaus J, Valledor AF,
López-López C, Pennington DJ and Celada A: PKC epsilon is involved
in JNK activation that mediates LPS-induced TNF-alpha, which
induces apoptosis in macrophages. Am J Physiol Cell Physiol.
285:C1235–1245. 2003. View Article : Google Scholar
|
|
96
|
Rajabi H and Kufe D: MUC1-C oncoprotein
integrates a program of EMT, epigenetic reprogramming and immune
evasion in human carcinomas. Biochim Biophys Acta Rev Cancer.
1868:117–122. 2017. View Article : Google Scholar
|
|
97
|
Rajabi H, Hiraki M and Kufe D: MUC1-C
activates polycomb complexes and downregulates tumor suppressor
genes in human cancer cells. Oncogene. 37:2079–2088. 2018.
View Article : Google Scholar
|
|
98
|
Wei MC, Zong WX, Cheng EH, Lindsten T,
Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and
Korsmeyer SJ: Proapoptotic BAX and BAK: A requisite gateway to
mitochondrial dysfunction and death. Science. 292:727–730. 2001.
View Article : Google Scholar
|
|
99
|
Westphal D, Dewson G, Czabotar PE and
Kluck RM: Molecular biology of Bax and Bak activation and action.
Biochim Biophys Acta. 1813:521–531. 2011. View Article : Google Scholar
|
|
100
|
Peña-Blanco A and García-Sáez AJ: Bax, Bak
and beyond - mitochondrial performance in apoptosis. FEBS J.
285:416–431. 2018. View Article : Google Scholar
|
|
101
|
Ahmad R, Alam M, Rajabi H and Kufe D: The
MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX
protein and blocks BAX function. J Biol Chem. 287:20866–20875.
2012. View Article : Google Scholar
|
|
102
|
D'Alessio M, De Nicola M, Coppola S,
Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P,
Ciriolo MR, Bergamaschi A, et al: Oxidative Bax dimerization
promotes its translocation to mitochondria independently of
apoptosis. FASEB J. 19:1504–1506. 2005. View Article : Google Scholar
|
|
103
|
Leng Y, Cao C, Ren J, Huang L, Chen D, Ito
M and Kufe D: Nuclear import of the MUC1-C oncoprotein is mediated
by nucleoporin Nup62. J Biol Chem. 282:19321–19330. 2007.
View Article : Google Scholar
|
|
104
|
Cangul H, Broday L, Salnikow K, Sutherland
J, Peng W, Zhang Q, Poltaratsky V, Yee H, Zoroddu MA and Costa M:
Molecular mechanisms of nickel carcinogenesis. Toxicol Lett.
127:69–75. 2002. View Article : Google Scholar
|
|
105
|
Lu H, Shi X, Costa M and Huang C:
Carcinogenic effect of nickel compounds. Mol Cell Biochem.
279:45–67. 2005. View Article : Google Scholar
|
|
106
|
Castorina A and Giunta S: Mucin 1 (MUC1)
signalling contributes to increase the resistance to cell death in
human bronchial epithelial cells exposed to nickel acetate.
Biometals. 27:1149–1158. 2014. View Article : Google Scholar
|
|
107
|
Schroeder JA, Masri AA, Adriance MC,
Tessier JC, Kotlarczyk KL, Thompson MC and Gendler SJ: MUC1
overexpression results in mammary gland tumorigenesis and prolonged
alveolar differentiation. Oncogene. 23:5739–5747. 2004. View Article : Google Scholar
|
|
108
|
Raina D, Kosugi M, Ahmad R, Panchamoorthy
G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S
and Kufe D: Dependence on the MUC1-C oncoprotein in non-small cell
lung cancer cells. Mol Cancer Ther. 10:806–816. 2011. View Article : Google Scholar
|
|
109
|
Andjelic S, Hsia C, Suzuki H, Kadowaki T,
Koyasu S and Liou HC: Phosphatidylinositol 3-kinase and NF-kappa
B/Rel are at the divergence of CD40-mediated proliferation and
survival pathways. J Immunol. 165:3860–3867. 2000. View Article : Google Scholar
|
|
110
|
Ahmad R, Raina D, Joshi MD, Kawano T, Ren
J, Kharbanda S and Kufe D: MUC1-C oncoprotein functions as a direct
activator of the nuclear factor-kappaB p65 transcription factor.
Cancer Res. 69:7013–7021. 2009. View Article : Google Scholar
|
|
111
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar
|
|
112
|
Datta SR, Katsov A, Hu L, Petros A, Fesik
SW, Yaffe MB and Greenberg ME: 143-3 proteins and survival kinases
cooperate to inactivate BAD by BH3 domain phosphorylation. Mol
Cell. 6:41–51. 2000. View Article : Google Scholar
|
|
113
|
Fleury C, Mignotte B and Vayssière JL:
Mitochondrial reactive oxygen species in cell death signaling.
Biochimie. 84:131–141. 2002. View Article : Google Scholar
|
|
114
|
Redza-Dutordoir M and Averill-Bates DA:
Activation of apoptosis signalling pathways by reactive oxygen
species. Biochim Biophys Acta. 1863:2977–2992. 2016. View Article : Google Scholar
|
|
115
|
Yin L, Huang L and Kufe D: MUC1
oncoprotein activates the FOXO3a transcription factor in a survival
response to oxidative stress. J Biol Chem. 279:45721–45727. 2004.
View Article : Google Scholar
|
|
116
|
Park JA, Park S, Choi JK, Han MK and Lee
Y: Inhibition of MUC1-C Increases ROS and Cell Death in Mouse
Embryonic Stem Cells. Int J Stem Cells. 14:180–190. 2021.
|
|
117
|
Liu Y, Ao X, Ding W, Ponnusamy M, Wu W,
Hao X, Yu W, Wang Y, Li P and Wang J: Critical role of FOXO3a in
carcinogenesis. Mol Cancer. 17:1042018. View Article : Google Scholar
|
|
118
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar
|
|
119
|
Amaral JD, Xavier JM, Steer CJ and
Rodrigues CM: The role of p53 in apoptosis. Discov Med. 9:145–152.
2010.
|
|
120
|
Wei X, Xu H and Kufe D: Human MUC1
oncoprotein regulates p53 responsive gene transcription in the
genotoxic stress response. Cancer Cell. 7:167–178. 2005. View Article : Google Scholar
|
|
121
|
Huang HZ, Yin YF, Wan WJ, Xia D, Wang R
and Shen XM: Up-regulation of microRNA-136 induces apoptosis and
radiosensitivity of esophageal squamous cell carcinoma cells by
inhibiting the expression of MUC1. Exp Mol Pathol. 110:1042782019.
View Article : Google Scholar
|
|
122
|
Wang JJ, Li ZF, Li XJ, Han Z, Zhang L and
Liu ZJ: Effects of microRNA-136 on melanoma cell proliferation,
apoptosis, and epithelial-mesenchymal transition by targetting PMEL
through the Wnt signaling pathway. Biosci Rep. 37:BSR201707432017.
View Article : Google Scholar
|
|
123
|
Wang L, Wu X, Wang B, Wang Q and Han L:
Mechanisms of miR-145 regulating invasion and metastasis of ovarian
carcinoma. Am J Transl Res. 9:3443–3451. 2017.
|
|
124
|
Wang X, Zhou X, Zeng F, Wu X and Li H:
miR-485-5p inhibits the progression of breast cancer cells by
negatively regulating MUC1. Breast Cancer. 27:765–775. 2020.
View Article : Google Scholar
|
|
125
|
Du C, Fang M, Li Y, Li L and Wang X: Smac,
a mitochondrial protein that promotes cytochrome c-dependent
caspase activation by eliminating IAP inhibition. Cell. 102:33–42.
2000. View Article : Google Scholar
|
|
126
|
Tummers B and Green DR: Caspase-8:
Regulating life and death. Immunol Rev. 277:76–89. 2017. View Article : Google Scholar
|
|
127
|
Ren J, Raina D, Chen W, Li G, Huang L and
Kufe D: MUC1 oncoprotein functions in activation of fibroblast
growth factor receptor signaling. Mol Cancer Res. 4:873–883. 2006.
View Article : Google Scholar
|
|
128
|
Chen Q, Li D, Ren J, Li C and Xiao ZX:
MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress.
Biochem Biophys Res Commun. 440:179–183. 2013. View Article : Google Scholar
|
|
129
|
Dunn C, Wiltshire C, MacLaren A and
Gillespie DA: Molecular mechanism and biological functions of c-Jun
N-terminal kinase signalling via the c-Jun transcription factor.
Cell Signal. 14:585–593. 2002. View Article : Google Scholar
|
|
130
|
Yarza R, Vela S, Solas M and Ramirez MJ:
c-Jun N-terminal Kinase (JNK) signaling as a therapeutic target for
Alzheimer's disease. Front Pharmacol. 6:3212016. View Article : Google Scholar
|
|
131
|
Zhang AM, Chi XH, Bo ZQ, Huang XF and
Zhang J: MUC1 gene silencing inhibits proliferation, invasion, and
migration while promoting apoptosis of oral squamous cell carcinoma
cells. Biosci Rep. 39:BSR201821932019. View Article : Google Scholar
|
|
132
|
Tanaka Y, Terai Y, Kawaguchi H, Fujiwara
S, Yoo S, Tsunetoh S, Takai M, Kanemura M, Tanabe A and Ohmichi M:
Prognostic impact of EMT
(epithelial-mesenchymal-transition)-related protein expression in
endometrial cancer. Cancer Biol Ther. 14:13–19. 2013. View Article : Google Scholar
|
|
133
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar
|
|
134
|
Renauld JC: Class II cytokine receptors
and their ligands: Key antiviral and inflammatory modulators. Nat
Rev Immunol. 3:667–676. 2003. View Article : Google Scholar
|
|
135
|
Yi FT and Lu QP: Mucin 1 promotes
radioresistance in hepatocellular carcinoma cells through
activation of JAK2/STAT3 signaling. Oncol Lett. 14:7571–7576.
2017.
|
|
136
|
Kato K, Lillehoj EP and Kim KC: MUC1
regulates epithelial inflammation and apoptosis by PolyI:C through
inhibition of Toll/IL-1 receptor-domain-containing adapter-inducing
IFN-β (TRIF) recruitment to Toll-like receptor 3. Am J Respir Cell
Mol Biol. 51:446–454. 2014. View Article : Google Scholar
|
|
137
|
Tréhoux S, Duchêne B, Jonckheere N and Van
Seuningen I: The MUC1 oncomucin regulates pancreatic cancer cell
biological properties and chemoresistance. Implication of p42-44
MAPK, Akt, Bcl-2 and MMP13 pathways. Biochem Biophys Res Commun.
456:757–762. 2015. View Article : Google Scholar
|
|
138
|
Xu X, Wells A, Padilla MT, Kato K, Kim KC
and Lin Y: A signaling pathway consisting of miR-551b, catalase and
MUC1 contributes to acquired apoptosis resistance and
chemoresistance. Carcinogenesis. 35:2457–2466. 2014. View Article : Google Scholar
|
|
139
|
Frisch SM and Ruoslahti E: Integrins and
anoikis. Curr Opin Cell Biol. 9:701–706. 1997. View Article : Google Scholar
|
|
140
|
Piyush T, Rhodes JM and Yu LG: MUC1
O-glycosylation contributes to anoikis resistance in epithelial
cancer cells. Cell Death Discov. 3:170442017. View Article : Google Scholar
|
